BMC Nephrol. 2013 Jul 8;14:138. doi: 10.1186/1471-2369-14-138.
Most kidney disorders involve some degree of inflammation, i.e. induction of pro-inflammatory mediators and leukocyte recruitment. But what are the factors that determine inflammation as a trigger or a consequence of kidney injury? Which types of renal inflammation can be targeted by the novel more selective immunosuppressive and anti-inflammatory agents? How to dissect the mechanisms behind innate and adaptive immune responses that are orchestrated inside or outside the kidney but both cause renal immunopathology i.e. renal inflammation? How to dissect leukocytic cell infiltrates into pro-inflammatory leukocytes from anti-inflammatory and pro-regenerative leukocytes? How to dissect leukocytes that support epithelial repair from those that promote renal fibrosis. The term 'renal inflammation' has moved far beyond the descriptive category of 'mixed leukocytic cell infiltrates' as commonly described in kidney biopsies. It is time to face the complexity of renal inflammation to finally benefit from the new age of novel immunomodulatory medicines.
大多数肾脏疾病都涉及一定程度的炎症,即诱导促炎介质和白细胞募集。但是,哪些因素决定了炎症是肾脏损伤的触发因素还是后果?新型更具选择性的免疫抑制和抗炎药物可以靶向哪些类型的肾炎症?如何剖析在肾脏内外协调但均导致肾免疫病理学(即肾炎症)的固有和适应性免疫反应的机制?如何剖析浸润白细胞从抗炎和促再生白细胞中转化为促炎白细胞?如何剖析促进上皮修复的白细胞与促进肾纤维化的白细胞。“肾脏炎症”一词已经远远超出了肾脏活检中通常描述的“混合白细胞浸润”这一描述性类别。现在是面对肾脏炎症的复杂性的时候了,以便最终从新型免疫调节药物的新时代中受益。